Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Stock Information for CohBar Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CohBar Inc.

CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FRGI, CWBR, SCU
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
CohBar Reports Second Quarter 2023 Financial Results
Moore Kuehn Encourages CWBR, KDNY, GHL, and EMAN Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WTT, CWBR, DM
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - PRTK, QUOT, CWBR, NEX
Moore Kuehn Encourages CWBR, KDNY, GHL, and DM Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.